Multiple treatments safe for forehead ‘11’ wrinkles: study
Good news for those of us with wrinkles between the eyebrows where we seem to be wearing the number “11” on our foreheads! A new study shows that multiple treatments of the wrinkle-relaxing injectable Dysport for those lines are not only well-tolerated and effective but also show no evidence of cumulative safety issues.
The study tracked 1,415 adult patients who were treated with Dysport – known generically as abobotulinumtoxinA – who received treatments for up to 24 months and then were monitored for safety for up to 36 months. Authors believe it’s the longest reported study evaluating the use of this popular injectable for ridding people of those parallel forehead lines that, by the way, are known as glabellar lines.
Nearly 40 health care practitioners – approximately three-quarters of them ASDS members – were involved through their participation with the Dysport Study Group. Because abobotulinumtoxinA injections must be repeated to prevent those frown lines from returning, the dermatologic surgeons said in the study report “it is essential to demonstrate that repeated administration over an extended period of time is safe and effective.” These patients were eligible for retreatment 85 or more days after the previous one.
Patients in the study had moderate or severe dynamic wrinkles at what dermatologic surgeons call “maximum frown.” (Bring your eyebrows together, wrinkling your forehead as if in a frown, and you’ll know immediately what that phrase means.)
Consumers gave their mark of approval to Dysport, Botox and Xeomin wrinkle relaxers in the 2013 ASDS Consumer Survey on Cosmetic Dermatologic Procedures. Asked to rate 10 specific cosmetic treatments, respondents gave wrinkle-relaxing injections a satisfaction rating of a whopping 92 percent.
In the same survey, 50 percent of consumers reported being somewhat to extremely bothered by those lines between their foreheads, indicating a desire to do something about them. After all, those turning to cosmetic procedures said they want to look as young as they feel or better for their age, and “want to appear more attractive.”
In 2013, ASDS members performed a total of 1.8 million wrinkle-relaxing injections, nearly 373,000 of them with Dysport, according to the ASDS Survey on Dermatologic Procedures.
Did the study find any downside to Dysport? A total of 991 patients reported primarily mild (69 percent) to moderate (20 percent) effects. These included injection site pain or bruising; headaches; coughs; and various eye issues, including drooping or twitching of the upper eyelid known as ptosis.
Physicians said most of the reported adverse events were later judged as either having nothing to do or probably nothing to do with the abobotulinumtoxinA injections.
“Long-term treatment with (Dysport) was well tolerated in patients with moderate to severe glabellar lines,” the study authors said. “Moreover, the tolerability and effectiveness observed with single treatments in short-term studies was maintained with repeat treatments over two years.”
The report – “Long-Term Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines: Results from a 36-Month, Multicenter, Open-Label Extension Study” – was published in February’s Dermatologic Surgery journal, the official publication of the American Society for Dermatologic Surgery. ASDS member Joel Schlessinger, MD, was the lead author.